MEKing Room: On the Quest for New Sources of Therapeutic Index in RAS/MAPK-Driven Cancers. (PubMed, Cancer Res) - Oct 16, 2026 - "At each drug's tolerability limit, atebimetinib outperformed the MEK inhibitor binimetinib across multiple RAS- and BRAF-mutant tumor models. Whether DCI or suppression of MEK phosphorylation is the primary driver of the improved therapeutic window and how atebimetinib compares with the clinical standard and other MEK-targeting agents remain important open questions, but the work makes a compelling case that novel pharmacology can unlock therapeutic spaces at targets long considered exhausted. See related article by Kolitz et al., p. 5223."
Journal • Oncology • BRAF
|
|
Bijaya Gaire; Poulikos I Poulikakos
|